Expertise in
28
conditions

Athimalaipet V. Ramanan

Upper Maudlin Street, 
Bristol, ENG, GB 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
28
conditions
Upper Maudlin Street, 
Bristol, ENG, GB 

Overview

Athimalaipet Ramanan practices practicing medicine in Bristol, United Kingdom.

Ramanan is highly rated in 28 conditions, according to our data. Their clinical expertise encompasses Juvenile Idiopathic Arthritis (JIA), Uveitis, Arthritis, and Chronic Recurrent Multifocal Osteomyelitis.

They are actively involved in clinical research, co-authoring 264 peer reviewed articles and participating in 10 clinical trials.

Locations

Upper Maudlin Street, Bristol, ENG, United Kingdom
Other Locations
Charlestown Road, Manchester, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Recruiting
Publish Date: August 24, 2026
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2026
Intervention Type: Drug
Study Drugs: Ixekizumab, Adalimumab
Study Phase: Phase 3
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
An Open-label, Active-Controlled, Safety, and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
An Open-label, Active-Controlled, Safety, and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Baricitinib, Adalimumab
Study Phase: Phase 3
Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial
Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Other, Biological
Study Drug: Adalimumab
Study Phase: Phase 4
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Completed
Publish Date: October 07, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
View 5 Less Clinical Trials

263 Total Publications

Bridging the gap between aspiration and reality in UK academic paediatrics.
Bridging the gap between aspiration and reality in UK academic paediatrics.
Journal: Archives of disease in childhood
Published: September 01, 2026

Frequently Asked Questions about Athimalaipet V. Ramanan

Is Athimalaipet V. Ramanan a top-rated expert for Juvenile Idiopathic Arthritis (JIA)?

MediFind is an objective health platform that identifies experts based on real-world data. Athimalaipet V. Ramanan is classified as an Elite expert for Juvenile Idiopathic Arthritis (JIA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Athimalaipet V. Ramanan participate in research or clinical trials?

Yes. Athimalaipet V. Ramanan has published 263 articles and abstracts on conditions like Juvenile Idiopathic Arthritis (JIA). You can view a list of Athimalaipet V. Ramanan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ramanan's expertise for a condition
ConditionClose
View All 21 Advanced Conditions
View All 44 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile